85 results about "Depression model" patented technology

Provided is a manufacturing method of a liver depression type gastric ulcer disease combined animal model. A gastric ulcer model is manufactured through an acidified ethanol solution belly-pouring method on the basis of manufacturing a liver depression model in traditional Chinese medicine syndrome differentiation through P.Willner traditional chronic unpredictability stimuli according to a Chinese medicine basic theory, comparison is conducted through an established animal macroscopic physical sign collection and evaluation table, and the animal model manufactured through the method conforms to clinical human disease attributes; the important attribute, namely, the lack of pleasant sensation, of human depression can be copied to an animal through the chronic unpredictability stimuli, and ulcer symptoms are accordingly exacerbated. In addition, the manufactured animal model better embodies the ordinary state of the gastric ulcer disease progress, clinical similarity is considered during model manufacturing, mechanisms of appearance, histomorphology, relapse and union of gastric ulcer are closest to those of a human body, it is avoided that whether it is pains and sag of operative wound type modeling or after-depression sag can not be distinguished, and convenience is provided for subsequent development.

The invention discloses a drug for treating depression. The drug is prepared by evenly mixing 0.3-99.7 parts by weight of industrial hemp seed extract and 99.7-0.3 parts by weight of industrial cannabinoid. It is proved through experiments that the drug can significantly shorten the tail suspension immobilization time of mice of a behavioral despair depression model and significantly shorten immobility time of forced swimming, has an obvious anti-depressant effect on a mouse depression model caused by reserpine and can significantly increase the frequency of spontaneous activities of the mice, and the effects are all superior to those of cannabidiol. The drug can be used for preparing drugs for treating various depression symptoms including endogenous depression, reactive depression, masked depression, secondary depression caused by drugs, climacteric or postnatal depression, depression caused by cerebral trauma or cerebral apoplexy, diabetes combined depression and depressive neurosis and used for preparing drugs for treating symptoms such as secondary learning memory decline and anhedonia caused by depression.

The invention discloses a Chinese medicinal composition for treating depression. The medicine adopts lilies, semen ziziphi apinosae, curcuma longa, hypericum perforatum L., perilla, ginseng, and radix bupleuri as raw materials, which are then separate and extracted by 0-75% ethanol so as to be prepared into certain preparation form. The above six drugs used together can soothe liver and relieve depression, reconcile and activate qi, tranquilize the mind and calm the nerves, and can be used for mild and moderate depression and patients belonging to stagnation of qi due to depression of liver, as well as heart-spleen deficiency. Pharmacodynamic research indicates that: the medicinal composition has substantial antagonistic effects on reserpine induced depression models, mouse akinesia and hypothermia, and can increase the spontaneous movements of tail suspension and forced swimming induced despair animal models, as well as the immobility time of tail suspension and swimming. Clinical research results show that a HAMD (Hamilton depression scale) used for evaluating depression severity and Chinese medicinal syndromes before and after treatment are taken as main curative effect indexes, which show that the Chinese medicinal composition in the invention has substantial curative effects. The composition provided in the invention can be prepared into medically acceptable oral preparations, such as tablets, capsules (soft capsules and hard capsules), granules, and other preparation forms. Clinical effects and pharmacodynamic research prove that the Chinese medicinal composition of the invention has the functions of liver soothing and depression relieving, mind tranquilizing as well as nerve calming, and is an effective medicine special for depression treatment.

The invention discloses a pharmaceutical composition for treating and preventing depression and a preparation method of the pharmaceutical composition. The composition consists of radix bupleuri extract, Chinese angelica extract and white atractylodes rhizome extract. According to the pharmacological experiment results, the pharmaceutical composition can be used for obviously reducing dead time in a mouse forced swimming test and a mice hanging test, remarkably increasing chronic temperature and the weight and the sweet water eccentricity of an unpredictable depression model, and has an obvious anti-depression effect which can reach or exceed that of the existing clinical common anti-depression drugs.

The invention relates to a traditional Chinese medicine (TCM) extract of total saponin ingredients and a preparation method of same. Raw materials for extracting the extract are 10-90 percent of lily and 10-90 percent of rhizoma anemarrhenae. All components are produced by adopting the following steps: purifying lily and rhizoma anemarrhenae, cleaning and then drying at low temperature of 50-70 DEG C; soaking lily and rhizoma anemarrhenae in alcohol, infiltering the alcohol and collecting alcohol liquor as A; adding water in residue for infiltration and collecting water solution as B; reclaiming A to alcohol to obtain a concentrated solution C with the herb weight of 1:1, and mixing B and C; filtering (a ceramic membrane) or micro-filtering; loading a P1P101 resin column at the speed of 2-3 ml/min for adsorption; and washing, backwashing with alcohol, concentrating, drying, crushing and screening. The invention has the advantages that as the extract contains saponin, a research shows that the extract can play a role of improving the symptom of a chronic stress induced depression model rat and can be used for curing human depression; and the preparation method is convenient, the cost is low, the implementation is easy, deficiencies in the prior art are made up, and a broad way is provided for development of the medicine industry.

The invention relates to a study method using capillary electrophoresis and UPLC-MS (ultra performance liquid chromatography - mass spectrometry) to analyze a regulating function of PQQ (pyrroloquinoline quinone) on catecholamine neurotransmitter, and belongs to the technical field of biological analysis. The method comprises the following steps of extracting brain tissues by anion solid-phase extraction, measuring the change of content of catecholamine in a mouse brain of a chronic stress induced depression model and the change of a reaction product of catecholamine, well separating PQQ, NE (noradrenaline), E (epinephrine) and products, and using UPLC-MS to identify the PQQ and the catecholamine reaction product. After proofing by results, the PQQ reacts with NE to generate the PQQNE, but does not react with E. The method has the advantages that the contents of NE in frontal lobe and hippocampus of the chronic stress induced depression model are obviously increased; by applying a certain amount of PQQ group, the content of NE is obviously decreased, and the contents of E in different groups are not obviously different; the PQQ is mainly used for regulating the catecholamine neurotransmitter through regulating the NE, but has no regulating function on E; the guidance meaning on the study of the depression disease mechanism and depression targeted medicine is realized.

The invention discloses a compound traditional Chinese medicine for treating depression. The compound traditional Chinese medicine taking Chinese herbaceous peony, radix bupleurim, turmeric, hyperforin perforatum, purple perilla, rhizoma anemarrhenae and long pepper as raw materials is extracted and separated by 0-75% ethanol and prepared as medically acceptable oral preparations such as troches, capsules (soft or hard capsules) and particles. The drafted major functions of the compound traditional Chinese medicine are soothing liver-qi stagnation and dispersing blood stasis and dredging collateral, and the compound traditional Chinese medicine is used for treating mild-to-moderate depression. The pharmacological researches show that the pharmaceutical composition can remarkably enhance open field activity of chronic stress depression mode mice and increase the consumption of sweet water; antagonizes akinesia and hypothermia of chronic stress depression mode mice induced by reserpine, so that the number of autonomic activities of despair animal mode induced by tail suspension and forced swimming and tail suspension and swimming immobility time are increased. The compound traditional Chinese medicine disclosed by the invention with the functions of soothing liver-qi stagnation is an effective special medicine for treating depression.

The invention discloses a construction method of a depression model for crab-eating macaques at adolescence and juvenility. The construction method comprises the steps of selecting 10 male crab-eatingmacaques at the adolescence, and dividing the selected crab-eating macaques into a chronic unpredictability stimulus group and a control group; performing 7-day daily treatment, and after adaptationis completed, performing 8-day baseline test; performing 5-cycle experiment while performing daily treatment on the chronic unpredictability stimulus group, including 7-day chronic unpredictable lightstimulus and 4-day behavior observation, performing daily treatment on the control group in the whole experiment process, and after every cycle is completed, also performing 4-day behavior observation; after the whole experiment cycle is completed, also performing apple desiring experiment and human intruder experiment on the chronic unpredictability stimulus group and the control group to respectively test the depression action and the anxiety-like action of the crab-eating macaques; collecting hair and plasma and performing cortisol content test; and finally, performing contrast with adolescent depression patients by a plasma metabonomics method. The model can provide reference for researching a potential mechanism of depression of teenagers in the future.

The invention discloses a compound preparation with an auxiliary effect of preventing and treating psychological depression of children and adolescents. The compound preparation comprises probiotic mineral powder, which comprises mineral and terpene components, a medicinal and edible component, a probiotic component and a vitamin component. Clinical contrast tests show that the compound preparation can well reduce the depression HAMD score of children and adolescents. Pharmacological tests of depression model mice show that the compound preparation provided by the invention obviously shortensthe immobility time of tail suspension in mice and obviously shortens the immobility time of forced swim in mice, and shows a very good anti-depression effect. Comparison tests show that the compoundpreparation provided by the invention is obviously superior to a single probiotic component or a mineral component and the medicinal and edible component thereof. All the components supplement each other and have a synergistic effect, and the treatment effect is achieved at multiple target points. The compound preparation is safe, effective and free of toxic and side effects.

The invention discloses a Chinese medicinal effective fraction composition for treating depression, comprising Hypericum perforatum extract containing Hypericum perforatum total flavonoids as effective fraction, Curcuma longa extract containing curcumin as effective fraction, and Panax ginseng extract containing ginsenoside as effective fraction. The invention can utilize the compatibility of the ingredients to treat depression, take multi-link, multi-path, multi-target action in soothing the liver, relieving the depressed liver, and relieving mental stress. The composition may be in the medically acceptable solid oral preparation in dosage form of such as tablet, capsule (soft capsule or hard capsule) and granule. Pharmacological research on effective fractions extracted from the formulation shows that the medicine has specific inhibitory effect on multiple depression models.

The invention discloses new medicinal application of 3,6'-disinapoyl sucrose (DISS), in particular the application of the 3,6'-disinapoyl sucrose (DISS) in preparing a product for treating tristimania. The 3,6'-disinapoyl sucrose (DISS) has better therapeutic effect on treating the tristimania caused by various reasons and obvious anti-depression activity to a pharmacological depression model, and the anti-depression activity of the 3,6'-disinapoyl sucrose is relative to the enhancement of the functions of 5-hydroxytryptamine (5-HT) and noradrenergic (NE) nerves. The DISS has no central excitation or inhibitive action within the range of an effective dosage of anti-depression.

The invention discloses a construction method of a mouse depression model. The method comprises the step of injecting 7-10 [mu] g of a serotonin neuron specific nerve poison into a dorsal raphe nucleus (DRN) area of a mouse. The 5, 7-DHT can be injected into the DRN of the mouse by adopting a stereotactic injection method, and the stable depression mouse model can be obtained 30 days after the nerve poison is injected. The invention provides the construction method of the mouse depression model with reduced brain serotonin content, which is characterized in that more than 90% of serotonin neurons in a DRN area of the mouse brain are accurately removed on the premise of ensuring high survival rate of animals and not influencing motor functions; and the mouse depression model simulates low serotonin content of clinical depression patients, is beneficial for scientists to explore pathogenesis of depression, and provides a research basis for screening and evaluation of different types of anti-depression drugs and treatment schemes.

The invention discloses a traditional Chinese medicine composition for treating depression. The traditional Chinese medicine composition is prepared by the following raw materials by mass: 1-6 parts of ginseng, 1-5 parts of polygala, 1-5 parts of grass leaved sweetflag, 1-6 parts of poria cocos, 1-6 parts of morinda officinalis, 1-5 parts of radix bupleuri, 1-5 parts of citrus aurantium, 1-6 parts of red paeonia and 1-5 parts of liquorice. The traditional Chinese medicine composition of the invention has the efficacy of invigorating qi, nourishing heart, soothing nerves, regulating qi and coursing liver, promoting blood circulation and relieving depression; and the combination of the medicine has the efficacy of invigorating qi and relieving depression. It is proved by pharmacodynamic tests that the traditional Chinese medicine composition can significantly improve the behavior abnormality of depression model rats with various types, has the efficacy of treating both the symptoms and root causes, and can effectively treat depression.

The invention relates to a new use of 20(S)-protopanoxadiol derivatives and 20(S)-protopanaxatriol derivatives, and mainly relates to a use in the preparation of medicines for treating or preventing depressive mental diseases. 20(S)-protopanoxadiol and 20(S)-protopanaxatriol are used as raw materials, and undergo oxidative cyclization to prepare dammara-20S-24(R)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,6beta,12beta,25-tetrol or dammara-20S-24(R)-epoxy-3beta,6beta,12beta,25-tetrol. Researches of pharmacological experiments show that dammara-20S-24(R/S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R/S)-epoxy-3beta,6beta,12beta,25-tetrol can obviously shorten the tail immobility time of mice in mouse tail suspension tests of a classic depression model, and can obviously shorten the swimming immobility time of the mice in mouse forced swimming model tests, so dammara-20S-24(R/S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R/S)-epoxy-3beta,6beta,12beta,25-tetraol have potential development values in the preparation of medicines for treating or preventing depressive mental diseases.

The invention relates to the technical field of medicines, and in particular to an application of andrographolide in preparing medicines for treating depression. Based upon researches with the assistance of various depression animal models and test methods, the andrographolide, through intraperitoneal injection, can obviously reverse various depression-like behaviors caused by the depression models, with efficacy intensity not weaker than that of a classical clinical anti-depression medicine, namely fluoxetine; therefore, as a completely new pharmacological effect, the andrographolide can be used for effectively relieving and treating the depression.

The invention belongs to the field of drugs, and particularly relates to an anti-depression drug and application thereof. The active ingredients of the anti-depression drug at least comprise friedelin, preferably, the active ingredients of the anti-depression drug include the friedelin and pachymic acid A. When the friedelin and the pachymic acid A are used as a composition, the weight part ratioof the the friedelin to the pachymic acid A in the anti-depression drug is (2-4):1. Oral tablets are preferably selected as the form of the anti-depression drug. The accessories of the oral tablets comprise hydroxypropyl methylcellulose, lactose, povidone K30, magnesium stearate and talcum powder. The drug has an improvement effect on the behavioral features, caused by chronic unpredictable mild stress, of a rat depression model.

The invention provides a depression detection method based on knowledge distillation and an emotion integration model, and relates to the technical field of depression models, and the method comprises the following steps: preprocessing answer texts of a plurality of depression-related questions and an external data set, wherein the data set is a microblog data set, and the microblog data set obtains user information according to questions and answers filled in a microblog by a user, so that a preprocessed microblog text and a text of question answering of the user are obtained; training an emotion classification model based on the preprocessed microblog text and a pre-training language model, wherein the pre-training language model is a Chinese pre-training BERT language model, and the Chinese pre-training BERT language model is used for predicting an emotion probability vector. According to the invention, the problems that the depression detection method based on the social media requires the user to have enough published content and behaviors on the social media and cannot process new users and users with sparse behaviors are solved.

The invention discloses a processing method of fructus gardeniae and antidepressant application of processed fructus gardeniae. The processing method includes the following steps: (1) taking fructus gardenia raw medicinal materials, and removing non-medicinal parts such as impurities, fruit stalks and branches; (2) taking clean fructus gardeniae to be put in a microwave generator, controlling themicrowave power to be 300-800w, performing heating for 30-60s, taking out the heated fructus gardeniae and performing crushing; (3) mixing crushed fructus gardeniae and ginger juice evenly to be put in a container with a cover, and performing covered moistening for 1-2 hours; and (4) taking the fructus gardeniae obtained in the step 3 to be put in a hot air drying box, and performing drying untilthe color of the fructus gardenia deepens to be burnt yellow or burnt yellowish-brown to obtain the processed fructus gardenia. The ginger fructus gardenia obtained by the processing method provided by the invention can effectively alleviate the toxic and side effects of the fructus gardenia, and maintain the content of gardenoside and saffron pigments. The processing method is simple. The pharmacological experiment proves that the obtained ginger fructus gardenia can significantly improve the depressive behavior of chronic stress-induced depression model rats.

The invention discloses application of 17-hydroxy-jolkinolide B in preparation of an anti-depression drug. A tail suspension test and a forced swimming test are to place depression model animals in asevere environment, so that the animals cannot escape to generate discontinuously immobile despairing states. The anti-depression drug can relieve the despairing degrees of the depression model animals, so that the immobile states can be reversed, and the depression symptoms can be relieved. Experimental researches find that the 17-hydroxy-jolkinolide B can relieve the despairing degrees of depression model mice, and has an anti-depression effect, and therefore has a prospect of being developed into the anti-depression drug.

The invention discloses a compound beverage containing lycium ruthenicum and herba cistanches, and a manufacturing method thereof. The lycium ruthenicum is subjected to ultrasonic low-temperature extraction under pressure so as to obtain a normal lycium ruthenicum juice; herba cistanche decoction pieces are crushed and extracted so as to obtain a herba cistanche leaching solution; the herba cistanche leaching solution is uniformly mixed with the normal lycium ruthenicum juice; and the obtained mixture is subjected to blending, homogenization, rough filtration, filling, and sterilization so as to obtain the compound beverage containing the lycium ruthenicum and the herba cistanches. The compound beverage has a uniform and brightly purple color, a moderate sweet taste, a moderate sour taste, an aroma specific to the lycium ruthenicum, a soft and delicate mouth feel, uniform quality, and no deposition. A functional test indicates that for a mouse forced swimming and tail suspension model, the prepared compound beverage can significantly shorten the still time of the mouse forced swimming and tail suspension; and an open field test indicates that the compound beverage has no obvious influence on the autonomic activities of mice. Therefore, the compound beverage has an anti-depression effect on a mice depression model, and extensive practicability and exploitation value.

The invention discloses application of a rat model with depression related to a chronic pain in researching on an action mechanism and targets of an antidepressant on pain. According to the model, lumbar 5 spinal nerve of a rat is ligated to cause distinct mechanical hyperalgesia and abnormal pain, accomplished with depression symptom. Then the ligation is released, and the abnormal pain behaviors of animals gradually disappear, but the psychiatric symptoms continue to exist. The depression model prepared by the invention can simulate a clinical phenomenon which is that pains disappear but emotional disorders still exist after treatment for the chronic pain patients, and then the action mechanism and the targets of the antidepressant on pain is understood from the source.

A palm leaf extract is prepared by ultrasonic extracting pulverized palm leaf with ethanol, and establishing mouse depression model by chronic unpredictable stress to study the antidepressant effect of palm leaf extract. The results of sugar-water preference test, open-field test, novelty environment inhibition feeding test and hanging-tail behavior test showed that palm wood extract had obvious antidepressant effect, which provided a basis for clinical research.

The invention belongs to the technical field of medicines and in particular discloses application of male hippocampus japonicus to preparation of a medicine or a preparation for improving desperationand helplessness behaviors of depression. According to the application provided by the invention, a mouse depression model is established through chronic mild unpredictable stimulation and feed containing the male hippocampus japonicus is fed to a mouse; the depression behavior resisting effect of the male hippocampus japonicus is evaluated through a forced swimming test; a possible mechanism is detected through molecular biological techniques including an HPLC (High Performance Liquid Chromatography) and the like. The research finds out that changes of hippocampus brain area neurotransmittersand metabolites thereof of the mouse are regulated and controlled by the male hippocampus japonicus and an intracerebral neurotransmitter level of the mouse is recovered, so that the desperation andhelplessness behaviors induced by CUMS (Chronic Unpredictable Stress) are improved and a novel way is provided for researching and developing a new anti-depression medicine.

The invention relates to the field of medicines and in particular relates to application of an Ly6c monoclonal antibody in treating tristimania induced by inflammation of the central nervous system. In a model of mouse tristimania induced by the inflammation of the central nervous system, the Ly6chi mononuclear cells in the blood can be soaked to the central nervous system, so that the Ly6chi mononuclear cells are prompted to participate in the inflammation of the central nervous system. The depression behavior can be remarkably worsened by specifically gathering the Ly6chi mononuclear cells. Meanwhile, the depression behavior can be remarkably improved by utilizing the Ly6c antibody to specifically restrain the functions of the Ly6chi mononuclear cells. According to the results, the Ly6chi mononuclear cells have important action in treating the inflammation-related tristimania. Furthermore, the invention discloses the novel application of the Ly6c antibody in treating the inflammation-related tristimania.